JAMA Ophthalmology | Original Investigation

Representation of Women Among Individuals With Mild Variants in *ABCA4*-Associated Retinopathy A Meta-Analysis

Stéphanie S. Cornelis, MSc; Joanna IntHout, PhD; Esmee H. Runhart, MD, PhD; Olivier Grunewald, PhD; Siying Lin, PhD; Zelia Corradi, MSc; Mubeen Khan, PhD; Rebekkah J. Hitti-Malin, PhD; Laura Whelan, PhD; G. Jane Farrar, PhD; Dror Sharon, PhD; L. Ingeborgh van den Born, MD, PhD; Gavin Arno, PhD; Mark Simcoe, PhD; Michel Michaelides, MD, PhD; Andrew R. Webster, PhD; Susanne Roosing, PhD; Omar A. Mahroo, PhD; Claire-Marie Dhaenens, PhD; Frans P. M. Cremers, PhD; for the *ABCA4* Study Group

IMPORTANCE Previous studies indicated that female sex might be a modifier in Stargardt disease, which is an *ABCA4*-associated retinopathy.

OBJECTIVE To investigate whether women are overrepresented among individuals with *ABCA4*-associated retinopathy who are carrying at least 1 mild allele or carrying nonmild alleles.

DATA SOURCES Literature data, data from 2 European centers, and a new study. Data from a Radboudumc database and from the Rotterdam Eye Hospital were used for exploratory hypothesis testing.

STUDY SELECTION Studies investigating the sex ratio in individuals with *ABCA4*-AR and data from centers that collected *ABCA4* variant and sex data. The literature search was performed on February 1, 2023; data from the centers were from before 2023.

DATA EXTRACTION AND SYNTHESIS Random-effects meta-analyses were conducted to test whether the proportions of women among individuals with *ABCA4*-associated retinopathy with mild and nonmild variants differed from 0.5, including subgroup analyses for mild alleles. Sensitivity analyses were performed excluding data with possibly incomplete variant identification. χ^2 Tests were conducted to compare the proportions of women in adult-onset autosomal non-*ABCA4*-associated retinopathy and adult-onset *ABCA4*-associated retinopathy and to investigate if women with suspected *ABCA4*-associated retinopathy are more likely to obtain a genetic diagnosis. Data analyses were performed from March to October 2023.

MAIN OUTCOMES AND MEASURES Proportion of women per *ABCA4*-associated retinopathy group. The exploratory testing included sex ratio comparisons for individuals with *ABCA4*-associated retinopathy vs those with other autosomal retinopathies and for individuals with *ABCA4*-associated retinopathy who underwent genetic testing vs those who did not.

RESULTS Women were significantly overrepresented in the mild variant group (proportion, 0.59; 95% CI, 0.56-0.62; P < .001) but not in the nonmild variant group (proportion, 0.50; 95% CI, 0.46-0.54; P = .89). Sensitivity analyses confirmed these results. Subgroup analyses on mild variants showed differences in the proportions of women. Furthermore, in the Radboudumc database, the proportion of adult women among individuals with *ABCA4*-associated retinopathy (652/1154 = 0.56) was 0.10 (95% CI, 0.05-0.15) higher than among individuals with other retinopathies (280/602 = 0.47).

CONCLUSIONS AND RELEVANCE This meta-analysis supports the likelihood that sex is a modifier in developing *ABCA4*-associated retinopathy for individuals with a mild *ABCA4* allele. This finding may be relevant for prognosis predictions and recurrence risks for individuals with *ABCA4*-associated retinopathy. Future studies should further investigate whether the overrepresentation of women is caused by differences in the disease mechanism, by differences in health care-seeking behavior, or by health care discrimination between women and men with *ABCA4*-AR.

JAMA Ophthalmol. 2024;142(5):463-471. doi:10.1001/jamaophthalmol.2024.0660 Published online April 11, 2024. + Supplemental content

Author Affiliations: Author affiliations are listed at the end of this article.

Group Information: The members of the *ABCA4* Study Group appear in Supplement 3.

Corresponding Author: Frans P. M. Cremers, PhD, Department of Human Genetics, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands (frans.cremers@radboudumc.nl). he inherited retinal degeneration Stargardt disease (STGD1) is caused by biallelic pathogenic variants in *ABCA4*. Its clinical hallmarks are macular degeneration, fundus flecks, and peripapillary sparing of the retina.¹The disease has a highly variable onset but typically starts in the second decade of life.² Individuals with early- or late-onset retinopathy may not show all clinical hallmarks, and therefore the entire disease spectrum is described as *ABCA4*associated retinopathy (*ABCA4*-AR). *ABCA4*-AR is the most frequent heritable macular dystrophy.

ABCA4-AR is caused by the disrupted function of the ABCA4 protein that normally reduces the number of cyto-toxic molecules in photoreceptors and the retinal pigment epithelium. The combined severity of genetic variants, catego-rized as mild, moderately severe, and severe, relate to a more severe phenotype of *ABCA4*-AR, ranging from early-onset STGD1 and panretinal cone-rod dystrophy to intermediate and late-onset STGD1 (**Figure 1**A).^{3,4} Two mild variants usually do not cause *ABCA4*-AR.³

However, this ABCA4 genotype-phenotype model does not predict the penetrance of disease. The mild variant c.5603A>T⁵ has an allele frequency indicating that in the general population, only about 5% of people carrying this variant with a severe pathogenic variant in trans can be affected. Siblings with c.5603A>T and a same second ABCA4 variant have shown a difference of multiple decades in disease onset as well as discordance in disease penetrance, where men seem to be less (severely) affected.⁶ Follow-up studies also indicate reduced penetrance for other mild variants.^{4,7} Apart from reduced penetrance of variants that are present in biallelic individuals in whom disease is expected, the opposite has also been observed: individuals with an STGD1-like phenotype who have 2 mild variants.⁸⁻¹¹ These examples indicate that ABCA4-AR is possibly multifactorial: modifiers could impact the onset and severity of the disease.

Key Points

Question Are women overrepresented among different groups of *ABCA4*-associated retinopathy?

Findings In this meta-analysis including 6 cohorts and 3154 individuals, a significant overrepresentation of women was observed among individuals with *ABCA4*-associated retinopathy carrying a mild variant with reduced penetrance, but not among individuals with *ABCA4*-associated retinopathy without such a variant.

Meaning These findings indicate that among individuals with *ABCA4*-associated retinopathy carrying a mild *ABCA4* variant with reduced penetrance, sex is likely a modifying factor in developing *ABCA4*-associated retinopathy or in presenting to the clinic.

In 2020, Runhart et al⁷ found that the ratio of women to men with biallelic *ABCA4* variants who carry a noncomplex mild reduced penetrant (mild_rp) variant is higher compared with the ratio in patients carrying 2 nonmild variants, where the ratio equaled 1. Later, Lee et al¹² could not replicate these findings, reporting more women in both groups. Similar to the findings of Runhart et al,⁷ multiple studies examining more than 75 individuals with *ABCA4*-AR reported a higher number of women among individuals carrying *ABCA4* variants, while only 1 such study reported more men and 1 study reported approximately the same numbers of men and women.²

Overall, these studies might indicate that more women are affected by *ABCA4*-AR than men and that this difference is larger in the group of affected individuals with a mild_rp *ABCA4* variant. In the present study, meta-analyses were performed with published data^{7,12,13} and 3 novel datasets to further investigate whether women are overrepresented among individuals with *ABCA4*-AR who carry a known mild_rp variant as



A, Model showing the association between the *ABCA4* genotype and the retinal phenotype,^{1,3} including a possible modifier effect and the distinction between mild variants with complete penetrance and those with reduced penetrance. B, Suggested association between variant severity and remaining *ABCA4* function. Variant severity is depicted based on literature and the female:male proportion in this meta-analysis.

464 JAMA Ophthalmology May 2024 Volume 142, Number 5

	Lille University Hospital (scanning)		Lille University Hospital (exon sequencing)		Moorfields Eye Hospital London		Corradi et al, ¹³ (2023)	
Allele	Women	Men	Women	Men	Women	Men	Women	Men
ABCA4 mild_rp alleles								
c.2588G>C	7	9	6	5	39	33	NA	NA
c.3113C>T	3	NA	6	6	2	2	1	1
c.4253 + 43G>A	2	NA	10	2	5	2	8	3
c.5603A>T	4	NA	41	17	19	12	25	17
c.5714 + 5G>A	9	8	15	15	20	20	4	2
c.5882G>A	23	21	77	55	92	74	53	36
c.6089G>A	2	2	5	4	13	5	5	NA
c.2588G>C & c.5714 + 5G>A	NA	NA	NA	NA	1	NA	NA	NA
c.3113C>T & c.5714 + 5G>A	NA	NA	NA	NA	NA	1	NA	NA
c.5714 + 5G>A & c.5882G>A	NA	NA	1	NA	NA	NA	NA	NA
c.5714 + 5G>A (homozygous)	NA	NA	NA	NA	1	1	NA	NA
c.5882G>A (homozygous)	NA	1	1	NA	5	2	3	1
Total mild_rp	50	41	162	104	197	152	99	60
BCA4 nonmild alleles	88	65	189	190	199	252	57	55

Table. Study Participants From Novel Sources

well as among individuals with *ABCA4*-AR who do not carry such a variant.

Methods

Objective

Based on the hypothesis that sex is a modifying factor that impacts all groups of *ABCA4*-AR with a bigger effect in the milder range of the spectrum (Figure 1A), it was investigated whether women are overrepresented in 2 groups of individuals with *ABCA4*-AR: (1) a mild_rp group, individuals with a mild_rp variant, and a (2) nonmild group, individuals without known mild_rp variants.

This meta-analysis followed Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines.¹⁴ Data collection, sequencing methods, variant categorization and statistical analyses are described in the eMethods in Supplement 1 and eTables 4-6 in Supplement 2. In short, variants were categorized as mild as described earlier,⁷ apart from the exclusion of c.769-784C>T, which based on underrepresentation among STGD1 individuals was reclassified as benign (F.P.M. Cremers, unpublished data, April 2023). Additional variants that were suspected to be mild were categorized as uncertain and excluded from the nonmild groups. The literature search was performed on February 1, 2023; data from the centers were from before 2023.

Statistical Analysis

Random-effects meta-analyses were subdivided into main, exploratory, and sensitivity analyses for mild_rp and nonmild groups. Exploratory subgroup analyses were performed for mild_rp variants. In all aforementioned analyses, proportions of women were compared with 0.5. *P* values for the 2 main objectives were considered statistically significant if smaller than .025.

Exploratory analyses were conducted on genetic datasets from Radboudumc and Rotterdam Eye Hospital to compare the proportions of women among adult-onset *ABCA4*-AR vs autosomal (non-*ABCA4*) retinopathies and among adult individuals with a differential diagnosis including STGD1 who were referred for genetic testing vs those not referred for genetic testing.

Sensitivity analyses were performed excluding data with possibly incomplete variant identification. χ^2 Tests were conducted to compare the proportions of women in adult-onset autosomal non-*ABCA4*-AR and adult-onset *ABCA4*-AR and to investigate if women with suspected *ABCA4*-AR are more likely to obtain a genetic diagnosis. All meta-analyses were conducted with the statistical software R version 4.1.3 (R Foundation) between March and October 2023, using the inverse variance method within the metaprop function from the meta package version 6.5-0.11-13.

Results

Novel ABCA4 Variant Data

Data from 244 and 645 individuals with *ABCA4*-AR from scanning and exon-sequencing techniques, respectively, from Lille University Hospital were included in the study, as well as data from 800 individuals from Moorfields Eye Hospital London and 271 individuals described by Corradi et al.¹³ In total, these data included 18 individuals with 2 mild_rp noncomplex variants. Individuals with c.2588G>C without c.5603A>T were mainly reported in the scanning dataset from Lille University Hospital and the Moorfields Eye Hospital London dataset. These datasets likely reported only a few cases with c.5603A>T in cis because the latter variant was long considered benign because of its high frequency. An overview of the data are given in the **Table**.

Figure 2. Forest Plot of Proportions of Women Among Individuals With Mild Variants With Reduced Penetrance

Source	Proportion (95%
Runhart et al, ⁷ 2020 (Khan et al, ¹⁵ 2019)	0.59 (0.43-0.74
Runhart et al, ⁷ 2020 (Khan et al, ¹⁶ 2020)	0.64 (0.58-0.71
Lee et al, ¹² 2021	0.56 (0.51-0.62
Corradi et al, ¹³ 2023	0.62 (0.54-0.70
Lille University Hospital (scanning technique)	0.55 (0.44-0.65
Lille University Hospital (exon sequencing)	0.61 (0.55-0.67
Moorfields Eye Hospital, London	0.56 (0.51-0.62
Total	0.59 (0.56-0.62
95% Prediction interval	(0.54-0.64
Heterogeneity: $\chi_6^2 = 6.11 (P = .41); l^2 = 2\% (95\%)$ Test for H ₂ proportion of women = 0.5; $t_c = 6.77$	SCI, 0-71) 7 (P<.001)



Box sizes are proportionate to the number of individuals per study. Data from Khan et al were derived from 2 studies^{15,16} that were taken up separately in this meta-analysis. Data from Lille University Hospital were divided based on the technique used to identify genetic variants. The dashed line indicates the total

proportion of women; diamond, combined estimate of the proportion of women with the 95% confidence interval; black bar, prediction interval of the estimated combined proportion; dotted line, proportion of 0.5, with which the data were compared.

Figure 3. Forest Plot of Proportions of Women Among Individuals With Nonmild Variants

Source	Proportion (95% CI)			More r	nen	More wo	omen		
Runhart et al, ⁷ 2020 (Khan et al, ¹⁵ 2019)	0.45 (0.33-0.58)			-			_		
Runhart et al, ⁷ 2020 (Khan et al, ¹⁶ 2020)	0.51 (0.45-0.58)			_			_		
Lee et al, ¹² 2021	0.53 (0.48-0.58)				-	_			
Corradi et al, ¹³ 2023	0.51 (0.41-0.60)								
Lille University Hospital (scanning technique)	0.58 (0.49-0.65)				- dec				
Lille University Hospital (exon sequencing)	0.50 (0.45-0.55)			_	-	—			
Moorfields Eye Hospital, London	0.44 (0.39-0.49)		_		—				
Total	0.50 (0.46-0.54)			-	<	>			
95% Prediction interval	(0.41-0.60)								
Heterogeneity: $\chi_6^2 = 11.75$ (<i>P</i> = .07); <i>I</i> ² = 49% (95% Cl, 0-78) Test for H ₀ proportion of women = 0.5; <i>t</i> ₆ = 0.15 (<i>P</i> = .89)			35 0.4	0 0.45 Propo	0.5 ortior	0 0.55 (95% CI	0.60	0.65	0.7

Box sizes are proportionate with the number of individuals per study. Data from Khan et al were derived from 2 studies^{15,16} that were taken up separately in this meta-analysis. Data from Lille University Hospital were divided based on the technique used to identify genetic variants. The dashed line indicates the total

proportion of women; diamond, combined estimate of the proportion of women with the 95% confidence interval; black bar, prediction interval of the estimated combined proportion; dotted line, proportion of 0.5, with which the data were compared.

Proportion of Women in the MildRP and Nonmild Groups

The random-effects meta-analysis on the proportion of women in the mild_rp group shows that the proportion of women in this category is significantly higher than 0.5 (mean proportion, 0.59; 95% CI, 0.56-0.62; 95% prediction interval, 0.54-0.64; P < .001) (Figure 2^{15,16} and eTable 2 in Supplement 1), while the proportion of women in the nonmild group was estimated to be 0.50 (95% CI, 0.46-0.54; 95% prediction interval, 0.41-0.60; P = .89) (Figure 3^{15,16} and eTable 3 in Supplement 1). The sensitivity analyses show similar results (mean proportion for mild_rp, 0.61; 95% CI, 0.56-0.65; prediction interval, 0.53-0.67; mean proportion for nonmild, 0.51; 95% CI, 0.48-0.54; prediction interval, 0.46-0.56) (eFigures 1 and 2 in Supplement 1), indicating that the main findings are robust. Study differences in proportions of women may be caused by cultural and/or genetic differences.

The exploratory subgroup analyses on the specific mild_rp variants show differences between mild_rp variants (main analysis, **Figure 4** and eFigure 3; sensitivity analysis, eFigure 4 in Supplement 1). In the main analysis, variant c.6089G>A had the highest overall proportion of women (0.67; 95% CI, 0.54-0.77). Also c.5603A>T had a high proportion of women (0.64; 95% CI, 0.58-0.69). The variants c.2588G>C and c.5714 + 5G>A showed the lowest overall proportions of women (both 0.53 with 95% CI, 0.45-0.61). Only variants c.5603A>T, c.5882G>A and c.6089G>A excluded the proportion of 0.5 from their 95% confidence intervals.

Genetic Diagnoses in Adult Women and Men With *ABCA4*-AR and Autosomal Non-*ABCA4*-AR

Individuals with *ABCA4*-AR caused by mild_rp variants often experience a later onset of the disease than individuals without mild_rp variants. Therefore, the overrepresentation of women in the mild_rp group might be due to a difference in obtaining a diagnosis as a result of differences in health careseeking behavior between adult men and women. If this is true, an overrepresentation of women is also expected among adult individuals with other retinopathies. The exploratory hypothesis that the sex ratio in obtaining a genetic diagnosis in adults is different for individuals with *ABCA4*-AR than for individuals with non-*ABCA4*-AR was investigated by consulting a genetic inherited retinal disease (IRD) database of the

Figure 4. Summarized Forest Plot of Proportions of Women Among Individuals With Specific Mild Variants With Reduced Penetrance in the Main Analysis

Source	Proportion (95% CI)		More men	More women
Variant c.2588G>C				
Total	0.53 (0.45-0.61)			\diamond
Heterogeneity: $\chi_3^2 = 0.81 (P = .85); I^2 = 0\% (95\% CI, 0.85)$				
Variant c.3113C>T				
Total	0.56 (0.38-0.73)			
Heterogeneity: $\chi_5^2 = 3.5 (P = .62); I^2 = 0\% (95\% CI, 0.75)$				
Variant c.4253+43G>A				
Total	0.63 (0.48-0.76)			
Heterogeneity: χ_6^2 = 6.43 (<i>P</i> = .38); <i>I</i> ² = 7% (95% CI, 0-73)				
Variant c.5603A>T				
Total	0.64 (0.58-0.69)			\diamond
Heterogeneity: $\chi_6^2 = 4.41 (P = .62); I^2 = 0\% (95\% CI, 0.71)$				
Variant c.5714+5G>A				
Total	0.53 (0.45-0.61)			\bigcirc
Heterogeneity: $\chi_6^2 = 3.62 (P = .73); I^2 = 0\% (95\% CI, 0.71)$				
Variant c.5882G>A				
Total	0.58 (0.52-0.64)			\diamond
Heterogeneity: $\chi_6^2 = 9.4$ (P = .15); $I^2 = 36\%$ (95% CI, 0-73)				
Variant c.6089G>A				
Total	0.67 (0.54-0.77)			
Heterogeneity: χ_6^2 = 3.22 (P = .78); I ² = 0% (95% CI, 0-71)				
Variant c.769-784C>T				
Runhart et al, ⁷ 2020 (Khan et al, ¹⁶ 2020)	0.33 (0.01-0.91)			
2 Mild variants				
Total	0.55 (0.21-0.85)			
Heterogeneity: χ_4^2 = 5.12 (P = .28); I ² = 22% (95% CI, 0-67) Test for subgroup differences: χ_8^2 = 16.53 (P = .04)		0 0	0.2 0.4 Proporti	0.6 0.8 on (95% CI)

The diamonds indicate the combined estimate of the proportion of women with the 95% confidence interval per variant. The dark blue box indicates the data for c.769-784C>T, which were reported in Runhart et al⁷ and Khan et al.¹⁶ The dotted line indicates the proportion of 0.5, with which the data were compared.

Radboudumc for the number of women and men who are genetically diagnosed with an autosomal form of retinopathy and who had genetic material sent in for testing after their 18th birthdays. The proportion of women (652/1154 = 0.56) among individuals with *ABCA4*-AR, (mean [SD] age, 44.6 [17.0] years) was 0.10 higher (95% CI, 0.05-0.15) than the proportion of women (280/602 = 0.47) among individuals with a retinopathy caused by variants in another autosomal gene (mean [SD] age, 44.3 [14.8] years).

Genetic Diagnoses in Adult Women and Men With a Clinical STGD1 Diagnosis

The exploratory hypothesis that adult women are more likely than men to obtain a genetic diagnosis after having received a clinical diagnosis was tested. The proportion of women in Dutch patients from the Rotterdam Eye Hospital who were given a differential diagnosis including STGD1 at 18 years or older who were sent for genetic testing was compared with the proportion of women in patients who were not sent for genetic testing. The numbers of women and men among adult individuals who did not obtain a genetic diagnosis were 21 and 27, respectively, while among individuals who did obtain a genetic diagnosis, there were 74 women and 58 men. Although 78% of women (for whom testing status was known) had genetic testing vs 68% of men, the proportions of women between the genetically tested (0.56) and not genetically tested (0.44) groups was not different (difference, -0.12; 95% CI, -0.28 to 0.04).

Discussion

In 2020, a sex imbalance between patients with *ABCA4*-AR from multiple countries with mild_rp variants vs those without mild variants was reported.⁷ A later study from the United States could not significantly replicate this imbalance.¹² In this meta-analysis, data from both studies as well as new data from 3 European centers were analyzed to investigate if women are overrepresented among patients with mild_rp variants as well as among patients without known mild variants. The proportion of women was significantly higher than 0.5 among individuals with a mild_rp *ABCA4* variant. This effect was not observed among individuals without a known mild_rp variant.

Previous studies showed no significant difference in the age at onset or best-corrected visual acuity between women and men with the mild variants c.5603A>T or c.5882G>A, respectively. Lee et al¹² suggested that a sex imbalance may therefore not be caused by a difference in the biological disease mechanism between women and men and instead may be explained by a difference in health care-seeking behavior between women and men. Interestingly, when the sex data from adult individuals with an autosomal retinopathy other than *ABCA4*-AR, from an IRD database from Radboudumc, were compared with those with an *ABCA4*-AR, the proportion of women was higher in the group of individuals with *ABCA4*-AR. This suggests that the identified overrepresentation is specific for *ABCA4*-AR and might not be based on sex-specific

health care-seeking behavior, although there might be a discrepancy between seeking health care and obtaining a diagnosis. Sex may therefore be a modifying factor specifically for individuals with mild_rp variants.

Mild Variants

Subgroup analyses show that particularly c.5882G>A, c.5603A>T, and c.6089G>A show a high proportion of women (0.58, 0.64, and 0.67, respectively), of which the confidence intervals do not include 0.5. It may be expected that these proportions would be negatively associated with the estimated reduced penetrance of the variants. However, this does not clearly seem to be the case (eTable 1 in Supplement 1). Nevertheless, the mild_rp variants were placed in the genotype-phenotype model based on the overall proportion of women per variant, where a higher proportion of women is assumed to relate to a smaller negative effect on ABCA4 function (Figure 1B).

The individual mild_rp variants likely result in a spectrum of residual ABCA4 activity and thereby their pathogenic effects. We propose a quantitative model based on remaining ABCA4 activity. This may be true for splice variants resulting in variable proportions of differentially spliced messenger RNA transcripts, but missense variants might exert different spatiotemporal effects in photoreceptor cells and the retinal pigment epithelium (RPE). The variant c.5882G>A has been associated with a specific phenotype, possibly indicating a specific variant effect.¹⁷

Contradictory Findings on Causes of the Observed Sex Imbalance

Retrospective data from Runhart et al⁷ and Lee et al¹² indicate that women with mild_rp variants do not have an earlier onset or a worse visual acuity than men with mild_rp variants. However, in general, women with STGD1 do show an earlier age at onset than men.¹⁸ Furthermore, a Radboudumc genetic IRD database shows a difference between the proportions of women among individuals with *ABCA4*-AR and among individuals with autosomal retinopathies not associated with *ABCA4*, suggesting an *ABCA4*-specific effect.

Biological Sex Differences Possibly Impacting the *ABCA4*-AR Disease Mechanism

Diseases that are not directly related to sex-specific characteristics can still show differences in prevalence and expression between women and men.¹⁹⁻²¹ Moreover, sex differences in the retina have been observed in humans.²²⁻²⁴ Therefore, possible sex differences should be considered and investigated carefully.

No biological mechanism involved in *ABCA4*-AR is currently known to be associated with sex. One factor that might be investigated more closely is the effect of high-density lipoprotein (HDL) cholesterol levels, which are higher in women and have been suggested as possible risk factors in agerelated macular degeneration.²⁵ These have been localized in the RPE, ganglion cells, and rod photoreceptor cells, suggesting a retina-specific processing and maturation of HDL cholesterol.²⁶ Recently, the lipid profile of the RPE and the retina in general has been associated with STGD1,^{27,28} further suggesting a possible link between HDL cholesterol and STGD1. Furthermore, mitochondrial function, for which sex differences have been shown and which has been suggested to play a role in diseases that involve the RPE such as STGD1, could be investigated more.^{29,30} Finally, especially among teenagers with STGD1, more girls than boys are observed, which could indicate an association between hormones and disease onset.¹⁸

Behavioral Sex Differences Possibly Impacting Health Care-Seeking Behavior

Lee et al¹² suggest that a possible sex imbalance in STGD1 is likely caused by differences in health care-seeking behavior. Multiple studies indeed report that women are more likely to seek health care.³¹⁻³⁴ However, these studies do not control or barely control for sex-specific health care needs, which have been reported to likely exist³² and may be caused by increased health care needs during and years after fertility treatment and pregnancy,^{35,36} health care related to the menstrual cycle, perimenopause or menopause, and contraception.³⁷⁻⁴⁸ Interestingly, the difference in seeking health care between men and women is absent after the postmenopausal age of 65 years.³³

Apart from sex-specific health care needs, it has also become apparent that women historically have been receiving health care that has been designed for men,⁴⁹⁻⁵² is less effective for women, or may have adverse effects for women,⁵³ which could increase health care need. Moreover, studies show that women are often discriminated against in receiving the right health care, likely increasing the number of necessary visits.^{52,54,55}

Overall, a sex difference in health care-seeking behavior could still exist after correction for the possible increased health care needs of women. Several publications suggest that men may view health care seeking as "less masculine" and avoid health care.⁵⁶⁻⁵⁸ Furthermore, there might also be a sex difference specifically in seeking a genetic diagnosis.

Alternatively, a difference in health care-seeking behavior could be caused by confounding factors associated with sex or gender. Studies show that people with more academic education more often visit a specialist, get a genetic diagnosis, or test for genetic predisposition related to cancer.^{31,59} Therefore, the sex imbalance might partially be explained by factors such as education.

Possible Discrimination Impacting Medical Treatment

The latter study further reports that the type of education does not seem to be associated with an individual's obtaining genetic counseling.⁵⁹ They mention that physicians may refer individuals with certain educational backgrounds more than others, meaning that individuals may be discriminated based on their education.

Because women are reported to have less access to health care and seek less health care in middle- and low-income countries compared with high-income countries,⁶⁰⁻⁶⁴ it should be noted that this meta-analysis contains data from high-income countries. Therefore, if the identified overrepresentation of women in the group with mild_rp variants is caused

by, rather than just associated with, a difference in behavior or treatment, this effect might be specific to high-income countries. More specifically, it might be related to health care access, and possibly related to income, for participating individuals in research studies.

Limitations

With the expectation of modifiers influencing the disease outcome of individuals with *ABCA4*-AR, it was hypothesized that occasionally *ABCA4*-AR is caused by 2 mild_rp variants and, therefore, individuals with 2 mild_rp variants were included in the mild_rp groups. If sex is a modifier, the proportion of women in the group with 2 mild_rp variants might be even higher than among individuals with 1 mild_rp variant. The subgroup analysis results for individuals with 2 mild_rp variants (proportion, 0.55; 95% CI, 0.21-0.85) does not support this theory. However, the subgroup is small (24 patients) and could contain individuals who do not have *ABCA4*-AR as well as individuals in which additional *ABCA4* variants were missed, potentially creating a bias in the group.

Furthermore, the inclusion of c.2588G>C and c.5714 + 5G>A in the mild_rp category may be incorrect. Variant c.2588G>C commonly co-occurs with c.5603A>T. When not in cis with c.5603A>T, it most likely is benign (Z. Corradi, F.P.M. Cremers, unpublished data, 2023). Additionally, c.5714 + 5G>A has been indicated not to be a mild variant⁶⁵ and may reside

ARTICLE INFORMATION

Accepted for Publication: January 27, 2024. Published Online: April 11, 2024.

doi:10.1001/jamaophthalmol.2024.0660
Author Affiliations: Department of Human

Genetics, Radboud University Medical Center, Nijmegen, the Netherlands (Cornelis, Corradi, Khan, Hitti-Malin, Roosing, Cremers); Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands (IntHout); Rotterdam Ophthalmic Institute. The Rotterdam Eve Hospital. Rotterdam, the Netherlands (Runhart, van den Born); Lille Neuroscience & Cognition, University of Lille, Inserm, CHU Lille, Lille, France (Grunewald, Dhaenens); National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, London, United Kingdom (Lin, Arno, Simcoe, Michaelides, Webster, Mahroo); Max Planck Institute for Psycholinguistics, Nijmegen, the Netherlands (Khan); Smurfit Institute of Genetics, School of Genetics and Microbiology, Trinity College Dublin, Dublin, Ireland (Whelan, Farrar); Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel (Sharon).

Author Contributions: Dr Cremers had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Concept and design:* Cornelis, Khan, Michaelides, Webster, Roosing, Cremers. *Acquisition, analysis, or interpretation of data:* Cornelis, IntHout, Runhart, Grunewald, Lin, Corradi, Hitti-Malin, Whelan, Farrar, Sharon, van den Born, at the boundary of the intervals for mild and moderately severe variants (Figure 1B). However, the overall proportion of women in the group of mild_rp variants would be even higher if these variants were not included in this meta-analysis.

Finally, we assume that all individuals in this study are cisgender and that they are male or female. However, studies indicate that this is not the case for up to 2% of individuals.^{66,67} This could have affected the results, although such an effect would be limited.

Conclusions

This study shows that among individuals with an *ABCA4*-AR diagnosis who are recruited mainly from centers in the United States and western Europe, women are overrepresented in the group of individuals who have a mild_rp allele. Future studies should further investigate whether the overrepresentation of women is caused by differences in the disease mechanism, by differences in health care-seeking behavior, or by health care discrimination between women and men with *ABCA4*-AR. A sex difference in the disease mechanism would mean that women are at an approximately 1.4-fold increased risk of developing *ABCA4*-AR compared with men when they carry a mild_rp variant. This effect could be incorporated in earlier described risk estimates used for genetic counselling.⁶⁸

Arno, Simcoe, Michaelides, Webster, Roosing, Mahroo, Dhaenens, Cremers.

Drafting of the manuscript: Cornelis, IntHout, Khan, Hitti-Malin, Michaelides, Roosing, Dhaenens. *Critical review of the manuscript for important intellectual content*: Cornelis, IntHout, Runhart, Grunewald, Lin, Corradi, Whelan, Farrar, Sharon, van den Born, Arno, Simcoe, Michaelides, Webster, Roosing, Mahroo, Dhaenens, Cremers. *Statistical analysis*: Cornelis, IntHout, Runhart. *Obtained funding:* Farrar, Arno, Webster, Cremers. *Administrative, technical, or material support:* Grunewald, Khan, Whelan, Sharon, Simcoe, Mahroo, Cremers.

Supervision: IntHout, Farrar, van den Born, Arno, Michaelides, Webster, Roosing, Mahroo, Dhaenens, Cremers.

Conflict of Interest Disclosures: Dr Mahroo reported advisory board meeting fees from Janssen outside the submitted work. No other disclosures were reported.

Funding/Support: Studies of Ms Cornelis and Drs Roosing and Cremers were funded by the Foundation Fighting Blindness (grants BR-GE-0120-0775-LUMC, BR-GE-1018-0738-RAD, PPA-0517-0717-RAD) and Novartis. The work of Dr Roosing was funded by the Foundation Fighting Blindness (grant CD-GE-0621-0809-RAD and PPA-0622-0841-UCL). The studies of Drs Hitti-Malin and Cremers were supported by the Health Research Charities Ireland/Health Research Board Joint Funding Scheme (2020-007), Stichting Oogfonds Nederland (UZ 2020-17), Pro Retina Deutschland, Stichting tot Verbetering van het Lot der Blinden, Stichting voor Ooglijders, and Stichting Blindenhulp. Ms Corradi and Dr Cremers were supported by European Union's Horizon 2020 research and innovation programme Marie

Sklodowska-Curie Innovative Training Networks StarT (grant 813490). Dr Dhaenens was supported by Groupement de Coopération Sanitaire Interrégional G4 qui réunit les Centres Hospitaliers Universitaires Amiens, Caen, Lille et Rouen (GCS G4) and by the Fondation Stargardt France.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: Members of the *ABCA4* Study Group are listed in Supplement 3.

Data Sharing Statement: See Supplement 4.

Additional Contributions: We thank Charlie Bos, MA, for their advice on using inclusive language.

REFERENCES

1. Cremers FPM, Lee W, Collin RWJ, Allikmets R. Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. *Prog Retin Eye Res*. 2020;79: 100861. doi:10.1016/j.preteyeres.2020.100861

2. LOVD-ABCA4. The *ABCA4* gene homepage. Accessed March 11, 2024. https://databases.lovd. nl/shared/genes/ABCA4

3. Maugeri A, van Driel MA, van de Pol DJ, et al. The 2588G→C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt disease. Am J Hum Genet. 1999;64(4):1024-1035. doi:10.1086/302323

4. Runhart EH, Valkenburg D, Cornelis SS, et al. Late-onset Stargardt disease due to mild,

deep-intronic ABCA4 alleles. *Invest Ophthalmol Vis Sci.* 2019;60(13):4249-4256. doi:10.1167/iovs. 19-27524

5. Zernant J, Lee W, Collison FT, et al. Frequent hypomorphic alleles account for a significant fraction of ABCA4 disease and distinguish it from age-related macular degeneration. *J Med Genet*. 2017;54(6):404-412. doi:10.1136/jmedgenet-2017-104540

6. Runhart EH, Sangermano R, Cornelis SS, et al. The common ABCA4 variant p. Asn18681le shows nonpenetrance and variable expression of Stargardt disease when present in trans with severe variants. *Invest Ophthalmol Vis Sci.* 2018;59(8): 3220-3231. doi:10.1167/iovs.18-23881

7. Runhart EH, Khan M, Cornelis SS, et al; Disease Consortium Study Group. Association of sex with frequent and mild ABCA4 alleles in Stargardt disease. *JAMA Ophthalmol*. 2020; 138(10):1035-1042. doi:10.1001/jamaophthalmol. 2020.2990

8. Zanolli M, Oporto JI, Verdaguer JI, et al. Genetic testing for inherited ocular conditions in a developing country. *Ophthalmic Genet*. 2020;41 (1):36-40. doi:10.1080/13816810.2020.1734944

9. Burke TR, Fishman GA, Zernant J, et al. Retinal phenotypes in patients homozygous for the G1961E mutation in the ABCA4 gene. *Invest Ophthalmol Vis Sci*. 2012;53(8):4458-4467. doi:10.1167/iovs.11-9166

10. Rivera A, White K, Stöhr H, et al. A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. *Am J Hum Genet*. 2000;67(4):800-813. doi:10.1086/303090

11. Klevering BJ, Yzer S, Rohrschneider K, et al. Microarray-based mutation analysis of the ABCA4 (ABCR) gene in autosomal recessive cone-rod dystrophy and retinitis pigmentosa. *Eur J Hum Genet*. 2004;12(12):1024-1032. doi:10.1038/sj.ejhg.5201258

12. Lee W, Zernant J, Nagasaki T, Allikmets R. Reevaluating the association of sex with ABCA4 alleles in patients with Stargardt disease. *JAMA Ophthalmol*. 2021;139(6):654-657. doi:10.1001/ jamaophthalmol.2021.0460

13. Corradi Z, Khan M, Hitti-Malin R, et al. Targeted sequencing and in vitro splice assays shed light on ABCA4-associated retinopathies missing heritability. *HGG Adv*. 2023;4(4):100237. doi:10.1016/j.xhgg.2023.100237

 Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283 (15):2008-2012. doi:10.1001/jama.283.15.2008

15. Khan M, Cornelis SS, Khan MI, et al. Cost-effective molecular inversion probe-based ABCA4 sequencing reveals deep-intronic variants in Stargardt disease. *Hum Mutat*. 2019;40(10): 1749-1759 doi:10.1002/humu.23787

16. Khan M, Cornelis SS, Pozo-Valero MD, et al. Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands through integrated genomics and transcriptomics. *Genet Med*. 2020; 22(7):1235-1246 doi:10.1038/s41436-020-0787-4

17. Lee W, Schuerch K, Zernant J, et al. Genotypic spectrum and phenotype correlations of ABCA4-associated disease in patients of south Asian descent. *Eur J Hum Genet*. 2017;25(6):735-743. doi:10.1038/ejhg.2017.13

18. Runhart EH, Dhooge P, Meester-Smoor M, et al. Stargardt disease: monitoring incidence and diagnostic trends in the Netherlands using a nationwide disease registry. *Acta Ophthalmol.* 2022;100(4):395-402. doi:10.1111/aos.14996

19. Crimmins EM, Shim H, Zhang YS, Kim JK. Differences between men and women in mortality and the health dimensions of the morbidity process. *Clin Chem.* 2019;65(1):135-145. doi:10.1373/clinchem.2018.288332

20. Mitry D, Tuft S, McLeod D, Charteris DG. Laterality and gender imbalances in retinal detachment. *Graefes Arch Clin Exp Ophthalmol*. 2011;249(7):1109-1110. doi:10.1007/s00417-010-1529-0

21. Mahroo OA, Mitry D, Williamson TH, Shepherd A, Charteris DG, Hamilton RD. Exploring sex and laterality imbalances in patients undergoing laser retinopexy. *JAMA Ophthalmol*. 2015;133(11): 1334-1336. doi:10.1001/jamaophthalmol.2015.2731

22. Korot E, Pontikos N, Liu X, et al. Predicting sex from retinal fundus photographs using automated deep learning. *Sci Rep.* 2021;11(1):10286. doi:10.1038/s41598-021-89743-x

23. Won JY, Kim SE, Park YH. Effect of age and sex on retinal layer thickness and volume in normal eyes. *Medicine (Baltimore)*. 2016;95(46):e5441. doi:10.1097/MD.00000000005441

24. Nieves-Moreno M, Martínez-de-la-Casa JM, Morales-Fernández L, Sánchez-Jean R, Sáenz-Francés F, García-Feijoó J. Impacts of age and sex on retinal layer thicknesses measured by spectral domain optical coherence tomography with Spectralis. *PLoS One*. 2018;13(3):e0194169. doi:10.1371/journal.pone.0194169

25. Heesterbeek TJ, Lorés-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol Opt.* 2020;40(2):140-170. doi:10.1111/opo.12675

26. Tserentsoodol N, Gordiyenko NV, Pascual I, Lee JW, Fliesler SJ, Rodriguez IR. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. *Mol Vis*. 2006;12(1319):1319-1333.

27. Farnoodian M, Bose D, Barone F, et al. Retina and RPE lipid profile changes linked with ABCA4 associated Stargardt's maculopathy. *Pharmacol Ther.* 2023;249:108482. doi:10.1016/j.pharmthera.2023. 108482

28. Farnoodian M, Bose D, Khristov V, et al. Cell-autonomous lipid-handling defects in Stargardt iPSC-derived retinal pigment epithelium cells. *Stem Cell Reports*. 2022;17(11):2438-2450. doi:10.1016/j. stemcr.2022.10.001

29. Sultanova RF, Schibalski R, Yankelevich IA, Stadler K, Ilatovskaya DV. Sex differences in renal mitochondrial function: a hormone-gous opportunity for research. *Am J Physiol Renal Physiol.* 2020;319(6):F1117-F1124. doi:10.1152/ajprenal.00320. 2020

30. Tong Y, Zhang Z, Wang S. Role of mitochondria in retinal pigment epithelial aging and degeneration. *Front Aging*. 2022;3:926627. doi:10.3389/fragi.2022.926627

31. Dunlop S, Coyte PC, McIsaac W. Socio-economic status and the utilisation of

physicians' services: results from the Canadian National Population Health Survey. *Soc Sci Med*. 2000;51(1):123-133. doi:10.1016/S0277-9536(99) 00424-4

32. Cleary PD, Mechanic D, Greenley JR. Sex differences in medical care utilization: an empirical investigation. *J Health Soc Behav*. 1982;23(2):106-119. doi:10.2307/2136508

33. Nabalamba A, Millar WJ. Going to the doctor. *Health Rep.* 2007;18(1):23-35.

34. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract*. 2016;17(1):38. doi:10.1186/s12875-016-0440-0

35. Grandi SM, Hinkle SN, Mumford SL, et al. Long-term mortality in women with pregnancy loss and modification by race/ethnicity. *Am J Epidemiol*. 2022;191(5):787-799. doi:10.1093/aje/kwac023

36. Handa VL, Blomquist JL, Knoepp LR, Hoskey KA, McDermott KC, Muñoz A. Pelvic floor disorders 5-10 years after vaginal or cesarean childbirth. *Obstet Gynecol.* 2011;118(4):777-784. doi:10.1097/AOG.0b013e3182267f2f

37. Nillni YI, Toufexis DJ, Rohan KJ. Anxiety sensitivity, the menstrual cycle, and panic disorder: a putative neuroendocrine and psychological interaction. *Clin Psychol Rev.* 2011;31(7):1183-1191. doi:10.1016/j.cpr.2011.07.006

38. Leonardi M, Hicks C, El-Assaad F, El-Omar E, Condous G. Endometriosis and the microbiome: a systematic review. *BJOG*. 2020;127(2):239-249. doi:10.1111/1471-0528.15916

39. Pinkerton JV, Guico-Pabia CJ, Taylor HS. Menstrual cycle-related exacerbation of disease. *Am J Obstet Gynecol*. 2010;202(3):221-231. doi:10.1016/j.ajog.2009.07.061

40. Tersman Z, Collins A, Eneroth P. Cardiovascular responses to psychological and physiological stressors during the menstrual cycle. *Psychosom Med.* 1991;53(2):185-197. doi:10.1097/00006842-199103000-00008

41. Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of estrogens in menstrual migraine. *Cells*. 2022;11(8):1355. doi:10.3390/cells11081355

42. O'Reilly K, McDermid F, McInnes S, Peters K. An exploration of women's knowledge and experience of perimenopause and menopause: an integrative literature review. *J Clin Nurs*. 2023;32 (15-16):4528-4540.

43. White PA, Wildman BG. Factors related to medical help-seeking in women with menstrual discomfort. *Behav Res Ther*. 1986;24(4):471-474. doi:10.1016/0005-7967(86)90012-4

44. Khialani D, Rosendaal F, Vlieg AVH. Hormonal contraceptives and the risk of venous thrombosis. *Semin Thromb Hemost*. 2020;46(8):865-871. doi:10.1055/s-0040-1715793

45. Martin D, Sale C, Cooper SB, Elliott-Sale KJ. Period prevalence and perceived side effects of hormonal contraceptive use and the menstrual cycle in elite athletes. *Int J Sports Physiol Perform*. 2018;13(7):926-932. doi:10.1123/jjspp.2017-0330

46. Lundin C, Danielsson KG, Bixo M, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in

Original Investigation Research

the different phases of the treatment cycle: a double-blind, placebo-controlled randomized trial. *Psychoneuroendocrinology*. 2017;76:135-143. doi:10.1016/j.psyneuen.2016.11.033

47. O'Connell K, Davis AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. *Contraception*. 2007;75(4):299-304. doi:10.1016/j.contraception.2006.09.008

48. Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TM. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods. *Contraception*. 1995;52(6):363-369. doi:10.1016/ 0010-7824(95)00226-X

49. Farahani P. Sex/gender disparities in randomized controlled trials of statins: the impact of awareness efforts. *Clin Invest Med.* 2014;37(3): E163. doi:10.25011/cim.v37i3.21383

50. Sugimoto CR, Ahn YY, Smith E, Macaluso B, Larivière V. Factors affecting sex-related reporting in medical research: a cross-disciplinary bibliometric analysis. *Lancet*. 2019;393(10171): 550-559. doi:10.1016/S0140-6736(18)32995-7

51. Zakiniaeiz Y, Cosgrove KP, Potenza MN, Mazure CM. Balance of the sexes: addressing sex differences in preclinical research. *Yale J Biol Med*. 2016;89(2):255-259.

52. Lippi D, Bianucci R, Donell S. Gender medicine: its historical roots. *Postgrad Med J*. 2020;96 (1138):480-486. doi:10.1136/postgradmedj-2019-137452

53. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biol Sex Differ*. 2020;11(1):32. doi:10.1186/s13293-020-00308-5

54. Samulowitz A, Gremyr I, Eriksson E, Hensing G. "Brave men" and "emotional women": a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. *Pain Res Manag.* 2018:6358624. doi:10.1155/2018/6358624

55. Mondal B, Dubey JD. Gender discrimination in health-care expenditure: an analysis across the age-groups with special focus on the elderly. *Soc Sci Med*. 2020;258:113089. doi:10.1016/j.socscimed. 2020.113089

56. Noone JH, Stephens C. Men, masculine identities, and health care utilisation. *Sociol Health Illn*. 2008;30(5):711-725. doi:10.1111/j.1467-9566. 2008.01095.x

57. Courtenay WH. Engendering health: a social constructionist examination of men's health beliefs and behaviors. *Psychol Men Masc.* 2000;1(1):4. doi:10.1037/1524-9220.1.1.4

58. Courtenay WH. Constructions of masculinity and their influence on men's well-being: a theory of gender and health. *Soc Sci Med*. 2000;50(10): 1385-1401. doi:10.1016/S0277-9536(99)00390-1

59. van Riel E, van Dulmen S, Ausems MG. Who is being referred to cancer genetic counseling? characteristics of counselees and their referral. *J Community Genet*. 2012;3(4):265-274. doi:10.1007/s12687-012-0090-4

60. Azad AD, Charles AG, Ding Q, Trickey AW, Wren SM. The gender gap and healthcare: associations between gender roles and factors affecting healthcare access in Central Malawi, June-August 2017. *Arch Public Health*. 2020;78(1): 119. doi:10.1186/s13690-020-00497-w

61. Reid TD, Wren SM, Grudziak J, Maine R, Kajombo C, Charles AG. Sex disparities in access to surgical care at a single institution in Malawi. *World J Surg.* 2019;43(1):60-66. doi:10.1007/s00268-018-4775-7 **62**. Kapoor M, Agrawal D, Ravi S, Roy A, Subramanian SV, Guleria R. Missing female patients: an observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India. *BMJ Open*. 2019;9(8):e026850. doi:10.1136/bmiopen-2018-026850

63. Cleland CR, Matsinhe C, Makupa WU, Philippin H. Gender bias within a diabetic retinopathy screening programme in Tanzania. *Eye* (*Lond*). 2022;36(suppl 1):33-39. doi:10.1038/ s41433-022-02004-7

64. Mercer GD, Lyons P, Bassett K. Interventions to improve gender equity in eye care in low-middle income countries: a systematic review. *Ophthalmic Epidemiol*. 2019;26(3):189-199. doi:10.1080/09286586.2019.1574839

65. Sajovic J, Meglič A, Corradi Z, et al. ABCA4 variant c.5714+5G>A in trans with null alleles results in primary RPE damage. *Invest Ophthalmol Vis Sci.* 2023;64(12):33-33. doi:10.1167/iovs.64.12.33

66. Flores AR, Herman J, Gates GJ, Brown TN; Williams Institute. How many adults identify as transgender in the United States? Published June 2016. Accessed March 12, 2024. https:// williamsinstitute.law.ucla.edu/wp-content/uploads/ Trans-Adults-US-Aug-2016.pdf

67. Monro S, Crocetti D, Yeadon-Lee T. Intersex/variations of sex characteristics and DSD citizenship in the UK, Italy and Switzerland. *Citizensh Stud.* 2019;23(8):780-797. doi:10.1080/13621025.2019.1645813

68. Cornelis SS, Runhart EH, Bauwens M, et al. Personalized genetic counseling for Stargardt disease: offspring risk estimates based on variant severity. *Am J Hum Genet*. 2022;109(3):498-507. doi:10.1016/j.ajhg.2022.01.008